<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01486992</url>
  </required_header>
  <id_info>
    <org_study_id>N+FOLFIRI-AEC-4</org_study_id>
    <nct_id>NCT01486992</nct_id>
  </id_info>
  <brief_title>mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are few studies about 2nd line treatment in advanced esophageal carcinoma (AEC), some
      showed that irinotecan may be effective. The investigators previous study has shown the
      efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study,
      the investigators would like to observe the efficacy and safety of Nimotuzumab plus
      Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of
      PTX/DDP.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Esophageal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFIRI+Nimotuzumab</intervention_name>
    <description>irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw</description>
    <arm_group_label>Nimotuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed esophageal squamous carcinoma,failed to 1st line treatment of
             paclitaxel/cisplatin

          -  Age 18 to 75 years old

          -  Measurable disease according to the RECIST criteria(diameter of the lesion should be
             more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image
             should be less than 15 days before enrollment)

          -  Life expectancy of ≥3 month

          -  Karnofsky performance status ≥80

          -  WBC&gt;3,500/mm3, absolute neutrophil count ≥2000/mm3, platelet&gt;100,000/mm3,
             Hb&gt;9g/dl，Bilirubin level &lt; 1.0 times ULN，Serum creatinine &lt;1.0 times ULN，ALT and
             AST&lt;2.5 times ULN ，AKP &lt; 2.5 times ULN ，(≤5 times ULN in patients with liver
             metastases)(within 7 days before enrollment)

          -  No sever complication, such as active gastrointestinal bleeding, perforation,
             jaundice, obstruction, non-cancerous fever＞38℃；

          -  Normal ECG/cardiac function

          -  Good compliance

          -  Having signed informed consent

        Exclusion Criteria:

          -  More than 1 Previous systemic therapy for metastatic esophageal squamous carcinoma

          -  Known hypersensitivity to study drugs

          -  Tumor with length≥10cm, liver metastasis covers more than 50% of liver,or lung
             metastasis covers more than 25% of lung

          -  No measurable lesions, eg. pleural fluid and ascites

          -  Only with Other previous malignancy within 5 year, except non-melanoma skin cancer

          -  Heart failure or other sever organ dysfunction, eg. coronary artery disease,
             myocardial infarction within the last 6 months only Brain or bone metastasis

          -  Chronic diarrhea

          -  Mentally abnormal or disable cognition,including CNS metastasis

          -  Pregnancy or lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaodong zhang, MD</last_name>
    <phone>861088196175</phone>
    <email>zxd0829@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhang Xiaodong</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XIAODONG ZHANG, MD</last_name>
      <phone>861088196175</phone>
      <email>zxd0829@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <last_update_submitted>January 11, 2012</last_update_submitted>
  <last_update_submitted_qc>January 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>HEAD OF GI ONCOLOGY</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

